In conclusion, through different mouse models, we demonstrated that the use of HCQ to inhibit autophagy specifically causes KL tumors, but not KP tumors, to be sensitive to the MEK inhibitor Trametinib. Here, MAP2K7 is linked to keratosis pilaris.